Bivalirudin in percutaneous coronary intervention

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine

Background:

• Bivalirudin is a direct thrombin inhibitor used in percutaneous coronary intervention (PCI).
• It functions by reversibly binding to thrombin, inhibiting both circulating and fibrin-bound forms.
• Understanding its properties is crucial for optimizing its use in cardiovascular procedures.

Purpose of the Study:

• To review the chemistry, pharmacology, pharmacokinetics, pharmacodynamics, adverse effects, drug interactions, dosing, administration, and pharmacoeconomics of bivalirudin.
• To discuss clinical trials evaluating bivalirudin's efficacy and safety in PCI.

Main Methods:

• Review of existing literature and clinical trial data on bivalirudin.
• Analysis of bivalirudin's mechanism of action, pharmacokinetic profile, and clinical outcomes compared to unfractionated heparin (UFH).

Main Results:

• Bivalirudin demonstrates a rapid onset of action and a short half-life, primarily eliminated renally.
• Clinical trials show bivalirudin is at least as effective as UFH in preventing ischemic complications during PCI.
• In modern PCI settings, bivalirudin, especially with provisional glycoprotein IIb/IIIa inhibitors, shows favorable ischemic and bleeding outcomes compared to UFH.

Conclusions:

• Bivalirudin is a safe and effective alternative to UFH in PCI, offering comparable or superior efficacy and safety profiles.
• Its use, particularly with provisional glycoprotein IIb/IIIa inhibitors, represents an acceptable and improved alternative to standard care in PCI.
• Pharmacoeconomic data suggests bivalirudin may be cost-effective compared to combination therapies.